Several ganglioside GM3 analogs, containing a variety of lipophilic parts in place of the ceramide moiety have been synthesized. Glycosylation of (2S, 3R, 4E)-2-azido-3-0-benzoyl-4-octa-decen-l, 3-diol (2) with 0-(methyl 5-acetamido-4, 7, 8, 9-tetra-0-acetyl-3, 5-dideoxy-o-glycero-α-D-galacto-2-nonulopyranosylonate)-(2→3)-(2, 4-di-0-acetyl-6-0-benzoyl-ß-D-galactopyranosyl)-(l→4)-3-(1)-acetyl-2, 6-di-0-benzoyl-α-D-glucopyranosyl trichloroacetimidate (1) gave the 8-glycoside (5), which was converted, via selective reduction of the azide group, introduction of acyl groups, 0-deacylation, and de-esterification, into the desired compounds (10-12). On the other hand, coupling of 1 with 3-benzyloxycarbonyl-amino-1-propanol (3) or (2RS)-3-benzyloxycarbonylamino-2-0-benzoyl-1, 2-propanediol (4) gave the corresponding ß-glycosides 13 and 14, respectively. These were converted by N-debenzyloxycarbonylation, coupling with 2-tetradecylhexadecanoic acid, 0-deacylation, and hydrolysis of the methyl ester group, into the end products (17 and 18).
No takes yet. Share an insight, caveat, or question.
Hasegawa et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: